Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice

作者：Stephen J. Freedland, Ugo De Giorgi · 发表于：Future Oncology · 年份：2026 · DOI：10.1080/14796694.2026.2676559 · 被引用次数：1 · 研究领域：Prostate Cancer Treatment and Research、Prostate Cancer Diagnosis and Treatment、Urinary Bladder and Prostate Research

This podcast features two of the investigators from the phase III EMBARK trial (NCT02319837) in conversation. The primary results from EMBARK demonstrated meaningfully improved primary and key secondary efficacy outcomes, while maintaining quality of life, with enzalutamide with or without leuprolide versus leuprolide alone in patients with high-risk biochemically recurrent prostate cancer. Notably, there was a meaningful improvement in overall survival with enzalutamide plus leuprolide compared with leuprolide alone. In this third podcast in the EMBARK series, the speakers discuss the key findings from the subsequent (protocol-defined and post hoc) analyses of EMBARK, including clinically relevant secondary outcomes; efficacy endpoints by age, prior definitive therapy, and the definition of high-risk biochemical recurrence per European Association of Urology criteria; and patient-reported outcomes by treatment suspension status. The podcast will predominately focus on the real-world implications of these findings for clinical practice. Clinicaltrials.gov identifier NCT02319837.